Cargando…

Hepatocellular carcinoma: HCC

Detalles Bibliográficos
Autor principal:	Blum, Hubert E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2011
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206666/ https://www.ncbi.nlm.nih.gov/pubmed/22087121

Ejemplares similares

Human Hepatocellular Carcinoma (HCC)
por: Buonaguro, Luigi
Publicado: (2020)

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
por: Negri, Francesca, et al.
Publicado: (2021)

Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression
por: Kotsari, Maria, et al.
Publicado: (2023)

MRI in detection of hepatocellular carcinoma (HCC)
por: Digumarthy, Subba R, et al.
Publicado: (2005)

Emerging Therapies for Hepatocellular Carcinoma (HCC)
por: Chakraborty, Eesha, et al.
Publicado: (2022)

Advances in Immunotherapy for Hepatocellular Carcinoma (HCC)
por: Bicer, Fuat, et al.
Publicado: (2023)

Aspirin, chronic hepatitis B (CHB) and hepatocellular carcinoma (HCC)—will there ever be enough data?
por: Crane, Harry, et al.
Publicado: (2023)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

A Curious Case of Vanishing Hepatocellular Carcinoma (HCC)
por: Kwei-Nsoro, Robert, et al.
Publicado: (2023)

Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
por: De Battista, Davide, et al.
Publicado: (2021)

Serum visfatin and vaspin levels in hepatocellular carcinoma (HCC)
por: Pazgan-Simon, Monika, et al.
Publicado: (2020)

NF-Y Overexpression in Liver Hepatocellular Carcinoma (HCC)
por: Bezzecchi, Eugenia, et al.
Publicado: (2020)

Intratumor heterogeneity in HCC
por: Friemel, Juliane, et al.
Publicado: (2015)

Interferon-γ/IRF-1 pathway regulatory mechanisms of PD-L1 expression and relevance for immune checkpoint blockade in hepatocellular carcinoma (HCC)
por: Yan, Yihe, et al.
Publicado: (2021)

Liver resection is always a good choice for hepatocellular carcinoma (HCC) patients regardless of Barcelona Clinic Liver Cancer (BCLC) stage: the therapeutic hierarchy
por: Guarino, Maria, et al.
Publicado: (2020)

Palliative Liver Radiotherapy (RT) for Symptomatic Hepatocellular Carcinoma (HCC)
por: Yeung, Cynthia S. Y., et al.
Publicado: (2020)

Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC)
por: Zhao, Pin, et al.
Publicado: (2021)

Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
por: Huang, Jingquan, et al.
Publicado: (2023)

Molecular network of HCC aggressiveness
por: Kim, Sang Geon, et al.
Publicado: (2015)

Strategies for HCC target discovery
por: Molina-Sánchez, Pedro, et al.
Publicado: (2017)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Forfeited hepatogenesis program and increased embryonic stem cell traits in young hepatocellular carcinoma (HCC) comparing to elderly HCC
por: Wang, Hsei-Wei, et al.
Publicado: (2013)

RYBP expression is associated with better survival of patients with hepatocellular carcinoma (HCC) and responsiveness to chemotherapy of HCC cells in vitro and in vivo
por: Wang, Wei, et al.
Publicado: (2014)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver
por: Schütte, Kerstin, et al.
Publicado: (2014)

Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC)
por: Dai, Liping, et al.
Publicado: (2013)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Chitosan Nanoparticles for Therapy and Theranostics of Hepatocellular Carcinoma (HCC) and Liver-Targeting
por: Bonferoni, Maria Cristina, et al.
Publicado: (2020)

Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC)
por: Perfahl, H., et al.
Publicado: (2020)

Hepatocellular Carcinoma (HCC), Where do we stand? Current situation
por: Hafeez, Muhammad, et al.
Publicado: (2020)

Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment
por: Xing, Mengtao, et al.
Publicado: (2021)

Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy
por: Choucair, Khalil, et al.
Publicado: (2021)

An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)
por: Huang, Wei, et al.
Publicado: (2023)

Comparison between using hepatocellular carcinoma (HCC) risk scores and the HCC national guideline to identify high‐risk chronic hepatitis B patients for HCC surveillance in Thailand
por: Rattananukrom, Chitchai, et al.
Publicado: (2022)

Evolving therapies in the treatment of hepatocellular carcinoma
por: Spangenberg, Hans Christian, et al.
Publicado: (2008)

Transcriptomic analysis links hepatocellular carcinoma (HCC) in HZE ion irradiated mice to a human HCC subtype with favorable outcomes
por: Ding, Liang-Hao, et al.
Publicado: (2021)

Small molecule inhibitors of Late SV40 Factor (LSF) abrogate hepatocellular carcinoma (HCC): Evaluation using an endogenous HCC model
por: Rajasekaran, Devaraja, et al.
Publicado: (2015)

Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
por: Lin, Zhong-Zhe, et al.
Publicado: (2010)

Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC)
por: Hashiguchi, Motoyuki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t68mt09v9p6bt4v1mf3ijr12hs